Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women - Effect on lipids, coagulation factors, haematology and biochemistry

Maturitas

Volumn 42, Issue 2, 2002, Pages 157-164

  Perry, W ^a   Wiseman, R A ^b  

^a Endocrine Centre   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Biochemistry; Coagulation factors; Estradiol valerate; HRT; Norethisterone; Serum lipids

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; ESTRADIOL VALERATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; LUPUS ANTICOAGULANT; NORETHISTERONE; PROTEIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ESTROGEN THERAPY; HEMATOLOGY; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLISM; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE; VEIN THROMBOSIS;

ADULT; AGED; BLOOD COAGULATION FACTORS; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPIDS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROGESTERONE CONGENERS; TIME FACTORS;

EID: 0037172942     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00039-7     Document Type: Article

References (26)

1. Risk of venous thromboembolism in users of hormone replacement therapy
2. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
3. Prospective study of exogenous hormones and risk of pulmonary embolism in women
4. Postmenopausal oestrogen and progestin use and the risk of cardiovascular disease
5. Randomised trial of estrogen plus progestin for secondary prevention of coronary artery disease in postmenopausal women
6. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
7. Combined oral oestradiol valerate-norethisterone treatment over 3 years in postmenopausal women. 1. Clinical aspects and endometrial histology
8. Combined oral oestradiol valerate-norethisterone treatment over 3 years in postmenopausal women. Correlation between oestrogen levels and bone mineral density sites
9. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized double-blind placebo-controlled crossover study
10. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein (a) and other lipoproteins
11. A prospective controlled trial of six forms of hormone replacement therapy given to postmenopausal women
12. Coagulation factors in opposed and unopposed oestrogen treatment at the climacteric
13. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: A placebo-controlled study with nomegestrol acetate and estradiol
14. Effects of oral and transdermal estrogen/progesterone regimens in blood coagulation and fibrinolysis on postmenopausal women. A randomized controlled trial
15. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women
16. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy
17. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors
18. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
19. Effect of new cyclical sequential postmenopausal HRT on lipoprotein, apoprotein and thrombophilia profile
20. The effect of estrogen replacement therapy with or without progestogen on the fibrinolysis system and coagulation inhibitors in postmenopausal status
21. The risk of recurrent venous thromboembolism in patients with an Arg SO6 AE G in mutation in the gene factor V (Factor V Leiden)
22. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of the factor V Leiden mutation
23. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus
24. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus or discoid erythematosus
25. Hormone replacement therapy in systemic lupus erythematosus
26. Safety of hormonal therapy in postmenopausal patients with systemic lupus erythematosus